Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of The Medicines Company
NEW YORK, Feb. 11, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of The Medicines Company ("Medicines" or the "Company") (NasdaqGS: MDCO). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at firstname.lastname@example.org or 212-697-6484.
The investigation concerns whether Medicines and certain of its officers and/or directors have violated federal securities laws. On February 10, 2014, a report was published by the Food and Drug Administration ("FDA") regarding Medicines drug candidate Cangrelor, designed to prevent blood clots during heart artery-clearing angioplasty and stenting procedures. The report found that Cangrelor did not show superiority to an already approved drug, and that the clinical trials sponsored by Medicines were unethically and inappropriately administered including by delaying administration of the competing drug and lowering dosage of the competing drug. The FDA report stated that, "because the CHAMPION trials were conducted unethically. We can refuse approval of Cangrelor based on that fact alone."
On this news, Medicines shares fell $1.80 or 5.26% to close at $32.42 per share on February 10, 2014.
If you are aware of any facts relating to this investigation, or purchased shares of Medicines pursuant to the Offering and suffered losses on that investment, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC